Innovative manufacturing plant for allogeneic cellular therapies

Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART) contracted CRB to design and build the first phase of its clinical and commercial production facility in Raleigh, North Carolina.

The design accommodates the natural flow of operations and organizes the space to allow for flexibility and adaptation as cell and gene therapy technology advances. Additionally, the manufacturing areas and support spaces (labs, office, warehouse, and utilities) are positioned to enable ongoing production while new units are brought online to satisfy market demands.

The team leveraged design-assist capabilities of trusted trade partners to allow for schedule acceleration over a traditional project execution. Off-site fabrication of the modular mechanical room and pipe racks accelerated the delivery while optimizing long term maintainability.

Executed using our ONEsolution™ delivery method, the team was able to identify cost, schedule, and constructability risks during early phases of project development. Those risks were quantified, and plans were developed to mitigate. The collaborative risk analysis efforts of the team resulted in a project that was delivered on time and under budget.